Lumos Diagnostics Receives $5 Million Prepayment From US Distribution Partner, Shares Up 3%

MT Newswires Live

Apr 14

Lumos Diagnostics (ASX:LDX) has received a $5 million prepayment for product from US distribution partner PHASE Scientific, confirming that the US Food and Drug Administration's 510(k) clearance with CLIA waiver for FebriDx product satisfies the milestone requirements of the PHASE distribution agreement, according to a Tuesday Australian bourse filing.

The company said the $5 million represents a prepayment for future sales and will be recorded as revenue when the product is shipped, the filing added.

The company's shares rose 3% in recent Tuesday trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2627460149"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2627460149\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2627460149?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-14 09:21","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2627460149","market":"sg","top_or_hot":-1,"title":"Lumos Diagnostics Receives $5 Million Prepayment From US Distribution Partner, Shares Up 3%","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> (ASX:LDX) has received a $5 million prepayment for product from US distribution partner PHASE Scientific, confirming that the US Food and Drug Administration's 510(k) clearance with CLIA waiver for FebriDx product satisfies the milestone requirements of the PHASE distribution agreement, according to a Tuesday Australian bourse filing.</p><p>The company said the $5 million represents a prepayment for future sales and will be recorded as revenue when the product is shipped, the filing added.</p><p>The company's shares rose 3% in recent Tuesday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Lumos Diagnostics Receives $5 Million Prepayment From US Distribution Partner, Shares Up 3%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLumos Diagnostics Receives $5 Million Prepayment From US Distribution Partner, Shares Up 3%\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-14 09:21</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/LDXHF\">Lumos Diagnostics</a> (ASX:LDX) has received a $5 million prepayment for product from US distribution partner PHASE Scientific, confirming that the US Food and Drug Administration's 510(k) clearance with CLIA waiver for FebriDx product satisfies the milestone requirements of the PHASE distribution agreement, according to a Tuesday Australian bourse filing.</p><p>The company said the $5 million represents a prepayment for future sales and will be recorded as revenue when the product is shipped, the filing added.</p><p>The company's shares rose 3% in recent Tuesday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LDX.AU","symbol_name":"LUMOS DIAGNOSTICS HOLDINGS L","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2627460149","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2627460149","pubTimestamp":1776129696,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Lumos Diagnostics  has received a $5 million prepayment for product from US distribution partner PHASE Scientific, confirming that the US Food and Drug Administration's 510 clearance with CLIA waiver for FebriDx product satisfies the milestone requirements of the PHASE distribution agreement, according to a Tuesday Australian bourse filing.The company said the $5 million represents a prepayment for future sales and will be recorded as revenue when the product is shipped, the filing added.The company's shares rose 3% in recent Tuesday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LDX.AU":"LUMOS DIAGNOSTICS HOLDINGS L","BK7126":"医疗保健用品"},"translate_title":"Lumos Diagnostics收到美国分销合作伙伴500万美元预付款，股价上涨3%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LDX.AU":1},"content_text":"Lumos Diagnostics (ASX:LDX) has received a $5 million prepayment for product from US distribution partner PHASE Scientific, confirming that the US Food and Drug Administration's 510(k) clearance with CLIA waiver for FebriDx product satisfies the milestone requirements of the PHASE distribution agreement, according to a Tuesday Australian bourse filing.The company said the $5 million represents a prepayment for future sales and will be recorded as revenue when the product is shipped, the filing added.The company's shares rose 3% in recent Tuesday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}